{"id":"gsk1325760a","safety":{"commonSideEffects":[{"rate":null,"effect":"Immune-related adverse events (irAEs)"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Rash"}]},"_chembl":{"chemblId":"CHEMBL1111","moleculeType":"Small molecule","molecularWeight":"378.43"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"OX40 is an inducible T-cell co-stimulatory molecule that, when engaged by its ligand OX40L, amplifies T-cell proliferation, survival, and effector function. By antagonizing OX40, GSK1325760A removes a negative regulatory signal and promotes robust anti-tumor immune responses. This approach is designed to work synergistically with other immunotherapies, particularly PD-1/PD-L1 inhibitors, to overcome immune tolerance in cancer.","oneSentence":"GSK1325760A is a monoclonal antibody that blocks OX40, a co-stimulatory immune checkpoint receptor, to enhance T-cell activation and anti-tumor immunity.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:14:39.087Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced solid tumors (in combination with checkpoint inhibitors)"}]},"trialDetails":[{"nctId":"NCT04095286","phase":"PHASE1","title":"Relative Bioavailability Study of Marketed and Lower Dose Ambrisentan in Healthy Adult Participants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2019-09-30","conditions":"Hypertension, Pulmonary","enrollment":29},{"nctId":"NCT00424034","phase":"PHASE1","title":"A Study of GSK1325760A in Healthy Japanese Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-01","conditions":"Healthy Subjects","enrollment":32},{"nctId":"NCT00554619","phase":"PHASE3","title":"A Study to Evaluate GSK1325760A - a Long-Term Extension Study","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-02","conditions":"Pulmonary Arterial Hypertension, Hypertension, Pulmonary","enrollment":21},{"nctId":"NCT00540436","phase":"PHASE2","title":"Evaluate the Efficacy, Safety and Pharmacokinetics of GSK1325760A in the Treatment of Pulmonary Arterial Hypertension","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-08","conditions":"Hypertension, Pulmonary","enrollment":25}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Ambrisentan"],"phase":"phase_3","status":"active","brandName":"GSK1325760A","genericName":"GSK1325760A","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"GSK1325760A is a monoclonal antibody that blocks OX40, a co-stimulatory immune checkpoint receptor, to enhance T-cell activation and anti-tumor immunity. Used for Advanced solid tumors (in combination with checkpoint inhibitors).","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2019-03-28T00:00:00.000Z","mah":"ZYDUS PHARMS","brand_name_local":"AMBRISENTAN","application_number":"ANDA210058"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2019-03-28T00:00:00.000Z","mah":"SUN PHARM","brand_name_local":"AMBRISENTAN","application_number":"ANDA210784"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2019-03-28T00:00:00.000Z","mah":"WATSON LABS INC","brand_name_local":"AMBRISENTAN","application_number":"ANDA208252"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2019-04-10T00:00:00.000Z","mah":"SIGMAPHARM LABS LLC","brand_name_local":"AMBRISENTAN","application_number":"ANDA208354"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2019-04-26T00:00:00.000Z","mah":"CIPLA","brand_name_local":"AMBRISENTAN","application_number":"ANDA210715"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2022-05-19T00:00:00.000Z","mah":"APOTEX","brand_name_local":"AMBRISENTAN","application_number":"ANDA210701"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2022-07-21T00:00:00.000Z","mah":"AUROBINDO PHARMA","brand_name_local":"AMBRISENTAN","application_number":"ANDA216531"}],"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}